Personalized cancer immunotherapy using Systems Medicine approaches
暂无分享,去创建一个
Olaf Wolkenhauer | Julio Vera | Gerold Schuler | Shailendra K. Gupta | Tanushree Jaitly | Ulf Schmitz | O. Wolkenhauer | U. Schmitz | J. Vera | G. Schuler | S. Gupta | T. Jaitly
[1] G. Rose,et al. Antigenic determinants in proteins coincide with surface regions accessible to large probes (antibody domains). , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[2] Gajendra P. S. Raghava,et al. AlgPred: prediction of allergenic proteins and mapping of IgE epitopes , 2006, Nucleic Acids Res..
[3] Ira Mellman,et al. Designing vaccines based on biology of human dendritic cell subsets. , 2010, Immunity.
[4] Yanxin Huang,et al. Conformational B-Cell Epitope Prediction Method Based on Antigen Preprocessing and Mimotopes Analysis , 2015, BioMed research international.
[5] Shoba Ranganathan,et al. Modeling the structure of bound peptide ligands to major histocompatibility complex , 2004, Protein science : a publication of the Protein Society.
[6] M. Sadelain,et al. Abstract 3499: CD56 targeted chimeric antigen receptors for immunotherapy of multiple myeloma , 2012 .
[7] Vladimir Brusic,et al. Predictive Vaccinology: Optimisation of Predictions Using Support Vector Machine Classifiers , 2005, IDEAL.
[8] M. Wirth,et al. Tumor-Associated Antigens for Specific Immunotherapy of Prostate Cancer , 2012, Cancers.
[9] Magdalini Moutaftsi,et al. A consensus epitope prediction approach identifies the breadth of murine TCD8+-cell responses to vaccinia virus , 2006, Nature Biotechnology.
[10] A. Radunskaya,et al. Mixed Immunotherapy and Chemotherapy of Tumors: Modeling, Applications and Biological Interpretations , 2022 .
[11] Ellis L. Reinherz,et al. Enhancement to the RANKPEP resource for the prediction of peptide binding to MHC molecules using profiles , 2004, Immunogenetics.
[12] Vasant G Honavar,et al. Predicting linear B‐cell epitopes using string kernels , 2008, Journal of molecular recognition : JMR.
[13] F. Marincola,et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. , 2011, The New England journal of medicine.
[14] Shishir K. Gupta,et al. In silico accelerated identification of structurally conserved CD8+ and CD4+ T-cell epitopes in high-risk HPV types. , 2012, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.
[15] Andrew J. G. Simpson,et al. CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens , 2008, Nucleic Acids Res..
[16] A. Perelson,et al. Nonlinear dynamics of immunogenic tumors: parameter estimation and global bifurcation analysis. , 1994, Bulletin of mathematical biology.
[17] V. Brusic,et al. Bioinformatics for cancer immunotherapy target discovery , 2014, Cancer Immunology, Immunotherapy.
[18] Tilo Beyer,et al. Integrating Signals from the T-Cell Receptor and the Interleukin-2 Receptor , 2011, PLoS Comput. Biol..
[19] Shishir K. Gupta,et al. In silico CD4+ T-cell epitope prediction and HLA distribution analysis for the potential proteins of Neisseria meningitidis Serogroup B--a clue for vaccine development. , 2010, Vaccine.
[20] D. Flower,et al. Peptide binding to the HLA-DRB1 supertype: a proteochemometrics analysis. , 2010, European journal of medicinal chemistry.
[21] P. Srivastava,et al. Harnessing the antigenic fingerprint of each individual cancer for immunotherapy of human cancer: genomics shows a new way and its challenges , 2013, Cancer Immunology, Immunotherapy.
[22] Jérôme Lane,et al. IMGT®, the international ImMunoGeneTics information system® , 2004, Nucleic Acids Res..
[23] Xinglong Yu,et al. An introduction to epitope prediction methods and software , 2009, Reviews in medical virology.
[24] M. Socinski,et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. , 2014, The Lancet. Oncology.
[25] Bart Spiessens,et al. Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] O. Wolkenhauer,et al. Kinetic modeling-based detection of genetic signatures that provide chemoresistance via the E2F1-p73/DNp73-miR-205 network. , 2013, Cancer research.
[27] Peter P. Lee,et al. Modeling Protective Anti-Tumor Immunity via Preventative Cancer Vaccines Using a Hybrid Agent-based and Delay Differential Equation Approach , 2012, PLoS Comput. Biol..
[28] Weijing Sun,et al. Cancer immunotherapy in clinical practice—the past, present, and future , 2014, Chinese journal of cancer.
[29] Ping Zhang,et al. Searching of optimal vaccination schedules , 2009, IEEE Engineering in Medicine and Biology Magazine.
[30] Tin Wee Tan,et al. Methods and protocols for prediction of immunogenic epitopes , 2006, Briefings Bioinform..
[31] Pornpimol Charoentong,et al. Bioinformatics for cancer immunology and immunotherapy , 2012, Cancer Immunology, Immunotherapy.
[32] B. A. Jameson,et al. The antigenic index: a novel algorithm for predicting antigenic determinants , 1988, Comput. Appl. Biosci..
[33] Francesco Pappalardo,et al. Modeling the competition between lung metastases and the immune system using agents , 2010, BMC Bioinformatics.
[34] A. Alix,et al. Predictive estimation of protein linear epitopes by using the program PEOPLE. , 1999, Vaccine.
[35] Wei Li,et al. ElliPro: a new structure-based tool for the prediction of antibody epitopes , 2008, BMC Bioinformatics.
[36] Benjamin E. Gross,et al. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.
[37] U. Klein,et al. Article Transcriptional Regulation of Germinal Center B and Plasma Cell Fates by Dynamical Control of Irf4 , 2022 .
[38] Byung-Jun Yoon,et al. Hidden Markov Models and their Applications in Biological Sequence Analysis , 2009, Current genomics.
[39] Shishir K. Gupta,et al. Understanding the Mechanism of Atovaquone Drug Resistance in Plasmodium falciparum Cytochrome b Mutation Y268S Using Computational Methods , 2014, PloS one.
[40] P. Canoll,et al. Cancer-testis and melanocyte-differentiation antigen expression in malignant glioma and meningioma , 2012, Journal of Clinical Neuroscience.
[41] J. Rothbard,et al. Role of the polymorphic residues in HLA-DR molecules in allele-specific binding of peptide ligands. , 1994, Journal of immunology.
[42] Pierre Baldi,et al. COBEpro: a novel system for predicting continuous B-cell epitopes. , 2009, Protein engineering, design & selection : PEDS.
[43] Fenglin Lv,et al. Toward prediction of binding affinities between the MHC protein and its peptide ligands using quantitative structure-affinity relationship approach. , 2008, Protein and peptide letters.
[44] Vladimir Brusic,et al. Prediction of promiscuous peptides that bind HLA class I molecules , 2002, Immunology and cell biology.
[45] Pingping Guan,et al. EpiJen: a server for multistep T cell epitope prediction , 2006, BMC Bioinformatics.
[46] H. Pehamberger,et al. High-molecular-weight melanoma-associated antigen mimotope immunizations induce antibodies recognizing melanoma cells , 2005, Cancer Immunology, Immunotherapy.
[47] J. Agrewala,et al. In silico methods for predicting T-cell epitopes: Dr Jekyll or Mr Hyde? , 2009, Expert review of proteomics.
[48] K. Chou,et al. Prediction of linear B-cell epitopes using amino acid pair antigenicity scale , 2007, Amino Acids.
[49] Minoru Kanehisa,et al. MIMOX: a web tool for phage display based epitope mapping , 2006, BMC Bioinformatics.
[50] Lloyd J. Old,et al. Cancer/testis antigens, gametogenesis and cancer , 2005, Nature Reviews Cancer.
[51] F. Brasseur,et al. A mutated HLA-A2 molecule recognized by autologous cytotoxic T lymphocytes on a human renal cell carcinoma , 1996, The Journal of experimental medicine.
[52] David A. Lee,et al. Predicting protein function from sequence and structure , 2007, Nature Reviews Molecular Cell Biology.
[53] H Mamitsuka,et al. Predicting peptides that bind to MHC molecules using supervised learning of hidden markov models , 1998, Proteins.
[54] T. Elliott,et al. Poor correspondence between predicted and experimental binding of peptides to class I MHC molecules. , 2000, Tissue antigens.
[55] Marialva Sinigaglia,et al. CrossTope: a curate repository of 3D structures of immunogenic peptide: MHC complexes , 2013, Database J. Biol. Databases Curation.
[56] C. Chelala,et al. A global insight into a cancer transcriptional space using pancreatic data: importance, findings and flaws , 2011, Nucleic acids research.
[57] Mingming Jia,et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer , 2014, Nucleic Acids Res..
[58] Thierry Boon,et al. Tumor‐specific shared antigenic peptides recognized by human T cells , 2002, Immunological reviews.
[59] John Sidney,et al. Predicting population coverage of T-cell epitope-based diagnostics and vaccines , 2006, BMC Bioinformatics.
[60] Søren Buus,et al. Peptide binding specificity of major histocompatibility complex class I resolved into an array of apparently independent subspecificities: quantitation by peptide libraries and improved prediction of binding , 1996, European journal of immunology.
[61] Gajendra P. S. Raghava,et al. SVM based method for predicting HLA-DRB1*0401 binding peptides in an antigen sequence , 2004, Bioinform..
[62] O. Wolkenhauer,et al. Envisioning the Application of Systems Biology in Cancer Immunology , 2020, Cancer Immunology.
[63] I. Haworth,et al. Structure-based prediction of MHC-peptide association: algorithm comparison and application to cancer vaccine design. , 2007, Journal of molecular graphics & modelling.
[64] Grant Lythe,et al. How many dendritic cells are required to initiate a T-cell response? , 2012, Blood.
[65] Paul François,et al. Phenotypic model for early T-cell activation displaying sensitivity, specificity, and antagonism , 2013, Proceedings of the National Academy of Sciences.
[66] D. Flower,et al. QSAR and the Prediction of T-Cell Epitopes , 2008 .
[67] C. Wheeler,et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. , 2012, The Lancet. Oncology.
[68] N. Hacohen,et al. HLA-Binding Properties of Tumor Neoepitopes in Humans , 2014, Cancer Immunology Research.
[69] K. Akashi,et al. Clinical outcomes of a novel therapeutic vaccine with Tax peptide‐pulsed dendritic cells for adult T cell leukaemia/lymphoma in a pilot study , 2015, British journal of haematology.
[70] Alessandro Sette,et al. The Immune Epitope Database 2.0 , 2009, Nucleic Acids Res..
[71] H. Margalit,et al. Sequence features that correlate with MHC restriction. , 1994, Molecular immunology.
[72] J. Slansky,et al. Improving T cell responses to modified peptides in tumor vaccines , 2012, Immunologic Research.
[73] H. Rammensee,et al. The making of the dominant MHC class I ligand SYFPEITHI , 1998, European journal of immunology.
[74] K. Choudhury,et al. Precision Cancer Immunotherapy: Optimizing Dendritic Cell-based Strategies to Induce Tumor Antigen-specific T-cell Responses Against Individual Patient Tumors , 2015, Journal of immunotherapy.
[75] P. Kantoff,et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. , 2010, The New England journal of medicine.
[76] J. Becker,et al. Survivin-specific T-cell reactivity correlates with tumor response and patient survival: a phase-II peptide vaccination trial in metastatic melanoma , 2012, Cancer Immunology, Immunotherapy.
[77] F. Rojo,et al. Pharmacodynamics: biological activity of targeted therapies in clinical trials , 2007, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.
[78] Cliburn Chan,et al. Feedback control of T–cell receptor activation , 2004, Proceedings of the Royal Society of London. Series B: Biological Sciences.
[79] Yuri Kogan,et al. Predicting Outcomes of Prostate Cancer Immunotherapy by Personalized Mathematical Models , 2010, PloS one.
[80] Z. Trajanoski,et al. Somatically mutated tumor antigens in the quest for a more efficacious patient-oriented immunotherapy of cancer , 2014, Cancer Immunology, Immunotherapy.
[81] Pietro Liò,et al. Trends in modeling Biomedical Complex Systems , 2009, BMC Bioinformatics.
[82] Vasant Honavar,et al. Recent advances in B-cell epitope prediction methods , 2010, Immunome research.
[83] Yingdong Zhao,et al. Application of support vector machines for T-cell epitopes prediction , 2003, Bioinform..
[84] Y. Li,et al. An incoherent regulatory network architecture that orchestrates B cell diversification in response to antigen signaling , 2011, Molecular systems biology.
[85] Wei-Feng Xu,et al. PSMA mimotope isolated from phage displayed peptide library can induce PSMA specific immune response , 1999, Cell Research.
[86] J. Wolchok,et al. Antibody therapy of cancer , 2012, Nature Reviews Cancer.
[87] J. Castle,et al. Exploiting the mutanome for tumor vaccination. , 2012, Cancer research.
[88] S. Gupta,et al. Ethnicity-tailored novel set of ESAT-6 peptides for differentiating active and latent tuberculosis. , 2013, Tuberculosis.
[89] J. Sidney,et al. Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity , 2014, The Journal of experimental medicine.
[90] P. Karplus,et al. Prediction of chain flexibility in proteins , 1985, Naturwissenschaften.
[91] Z. Nagy,et al. Precise prediction of major histocompatibility complex class II-peptide interaction based on peptide side chain scanning , 1994, The Journal of experimental medicine.
[92] Nathalie Vigneron,et al. Database of T cell-defined human tumor antigens: the 2013 update. , 2013, Cancer immunity.
[93] K. Parker,et al. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. , 1994, Journal of immunology.
[94] S. Ferrone,et al. Targeting Melanoma Cells with Human High Molecular Weight-Melanoma Associated Antigen-Specific Antibodies Elicited by a Peptide Mimotope: Functional Effects , 2006, The Journal of Immunology.
[95] Y. Kogan,et al. Improving T-cell Immunotherapy for Melanoma Through a Mathematically Motivated Strategy: Efficacy in Numbers? , 2012, Journal of immunotherapy.
[96] F Castiglione,et al. Cancer immunotherapy, mathematical modeling and optimal control. , 2007, Journal of theoretical biology.
[97] Gajendra P. S. Raghava,et al. ProPred: prediction of HLA-DR binding sites , 2001, Bioinform..
[98] Julio Vera,et al. Optimization of biochemical systems through mathematical programming: Methods and applications , 2010, Comput. Oper. Res..
[99] J A Sherratt,et al. Pattern formation and spatiotemporal irregularity in a model for macrophage-tumour interactions. , 1997, Journal of theoretical biology.
[100] Zhide Hu,et al. QSAR method for prediction of protein-peptide binding affinity: application to MHC class I molecule HLA-A*0201. , 2007, Journal of molecular graphics & modelling.
[101] U. Şahin,et al. Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices , 1999, Nature Biotechnology.
[102] E. Jaffee,et al. The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors. , 2001, Cancer research.
[103] Martin A. Cheever,et al. PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer Vaccine , 2011, Clinical Cancer Research.
[104] James Robinson,et al. IPD—the Immuno Polymorphism Database , 2004, Nucleic acids research.
[105] O. Lund,et al. Prediction of residues in discontinuous B‐cell epitopes using protein 3D structures , 2006, Protein science : a publication of the Protein Society.
[106] Bashir A Akhoon,et al. In silico designing and optimization of anti-breast cancer antibody mimetic oligopeptide targeting HER-2 in women. , 2010, Journal of molecular graphics & modelling.
[107] L. Billingham,et al. Phase I/II trial of a dendritic cell vaccine transfected with DNA encoding melan A and gp100 for patients with metastatic melanoma , 2011, Gene Therapy.
[108] P. Barker,et al. Efficient Generation of Major Histocompatibility Complex Class I-Peptide Complexes Using Synthetic Peptide Libraries* , 1998, The Journal of Biological Chemistry.
[109] Timothy J. Lavelle,et al. Immunological network signatures of cancer progression and survival , 2011, BMC Medical Genomics.
[110] Joakim Dillner,et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. , 2010, Journal of the National Cancer Institute.
[111] K. R. Woods,et al. Prediction of protein antigenic determinants from amino acid sequences. , 1981, Proceedings of the National Academy of Sciences of the United States of America.
[112] V. Grantcharova,et al. Therapeutically Targeting ErbB3: A Key Node in Ligand-Induced Activation of the ErbB Receptor–PI3K Axis , 2009, Science Signaling.
[113] Morten Nielsen,et al. NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8–11 , 2008, Nucleic Acids Res..
[114] A. Radunskaya,et al. A Model of Dendritic Cell Therapy for Melanoma , 2013, Front. Oncol..
[115] Anne S De Groot,et al. Bioinformatics tools for identifying class I-restricted epitopes. , 2003, Methods.
[116] H. Bui,et al. Structural prediction of peptides binding to MHC class I molecules , 2006, Proteins.
[117] E Westhof,et al. Correlation between the location of antigenic sites and the prediction of turns in proteins. , 1993, Immunology letters.
[118] Johannes Söllner,et al. Selection and combination of machine learning classifiers for prediction of linear B‐cell epitopes on proteins , 2006, Journal of molecular recognition : JMR.
[119] John Sidney,et al. A Systematic Assessment of MHC Class II Peptide Binding Predictions and Evaluation of a Consensus Approach , 2008, PLoS Comput. Biol..
[120] Olaf Wolkenhauer,et al. Integration of sensitivity and bifurcation analysis to detect critical processes in a model combining signalling and cell population dynamics , 2010, Int. J. Syst. Sci..
[121] Syed Haider,et al. International Cancer Genome Consortium Data Portal—a one-stop shop for cancer genomics data , 2011, Database J. Biol. Databases Curation.
[122] T. Schumacher,et al. Neoantigens in cancer immunotherapy , 2015, Science.
[123] Yuri Kogan,et al. Reconsidering the paradigm of cancer immunotherapy by computationally aided real-time personalization. , 2012, Cancer research.
[124] O. Lund,et al. novel sequence representations Reliable prediction of T-cell epitopes using neural networks with , 2003 .
[125] P. Tighe,et al. Selection of peptide ligands for the antimucin core antibody C595 using phage display technology: definition of candidate epitopes for a cancer vaccine , 1995, Clinical molecular pathology.
[126] B. Schoeberl,et al. MM-141, an IGF-IR– and ErbB3-Directed Bispecific Antibody, Overcomes Network Adaptations That Limit Activity of IGF-IR Inhibitors , 2013, Molecular Cancer Therapeutics.
[127] James Robinson,et al. The IPD and IMGT/HLA database: allele variant databases , 2014, Nucleic Acids Res..
[128] D. Bowtell,et al. A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment. , 2012, Cancer research.
[129] Irini Doytchinova,et al. EpiDOCK: a molecular docking-based tool for MHC class II binding prediction. , 2013, Protein engineering, design & selection : PEDS.
[130] Ping Zhu,et al. MimoDB 2.0: a mimotope database and beyond , 2011, Nucleic Acids Res..
[131] M. Zanetti. Tapping CD4 T Cells for Cancer Immunotherapy: The Choice of Personalized Genomics , 2015, The Journal of Immunology.
[132] K. Kohn,et al. CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set. , 2012, Cancer research.
[133] Vladimir Brusic,et al. Prediction of MHC class II-binding peptides using an evolutionary algorithm and artificial neural network , 1998, Bioinform..
[134] Doron Levy,et al. A Mathematical Model of the Enhancement of Tumor Vaccine Efficacy by Immunotherapy , 2012, Bulletin of mathematical biology.
[135] Ruo-Pan Huang,et al. Tumor-induced perturbations of cytokines and immune cell networks. , 2014, Biochimica et biophysica acta.
[136] Rick Reitmaier,et al. Review of immunoinformatic approaches to in-silico B-cell epitope prediction , 2007 .
[137] J. Sidney,et al. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules , 1993, Cell.
[138] B. McMahon,et al. Hepatitis B immunity in children vaccinated with recombinant hepatitis B vaccine beginning at birth: a follow-up study at 15 years. , 2007, Vaccine.
[139] D. Madden. The three-dimensional structure of peptide-MHC complexes. , 1995, Annual review of immunology.
[140] F. Pappalardo,et al. In silico modeling and in vivo efficacy of cancer-preventive vaccinations. , 2010, Cancer research.
[141] Wei Zhang,et al. Mimotope vaccination for epitope-specific induction of anti-VEGF antibodies , 2013, BMC Biotechnology.
[142] H. Kalbacher,et al. New ligands binding to the human leukocyte antigen class II molecule DRB1*0101 based on the activity pattern of an undecapeptide library. , 1996, European journal of biochemistry.
[143] S. Rosenberg,et al. T Cells Associated with Tumor Regression Recognize Frameshifted Products of the CDKN2A Tumor Suppressor Gene Locus and a Mutated HLA Class I Gene Product , 2004, The Journal of Immunology.
[144] Kun Yu,et al. Methods for Prediction of Peptide Binding to MHC Molecules: A Comparative Study , 2002, Molecular medicine.
[145] Gajendra P.S. Raghava,et al. A hybrid approach for predicting promiscuous MHC class I restricted T cell epitopes , 2007, Journal of Biosciences.
[146] T. Lundstedt,et al. Development of proteo-chemometrics: a novel technology for the analysis of drug-receptor interactions. , 2001, Biochimica et biophysica acta.
[147] Irini Doytchinova,et al. T-cell epitope vaccine design by immunoinformatics , 2013, Open Biology.
[148] S. Tenzer,et al. Using the World Wide Web for predicting CTL epitopes. , 2003, Current opinion in immunology.
[149] L Raddrizzani,et al. In Vitro and In Vivo Induction of a Th Cell Response Toward Peptides of the Melanoma-Associated Glycoprotein 100 Protein Selected by the TEPITOPE Program1 , 2000, The Journal of Immunology.
[150] Naoki Abe,et al. Prediction of MHC Class I Binding Peptides by a Query Learning Algorithm Based on Hidden Markov Models , 2002, Journal of biological physics.
[151] Q. Xia,et al. Quantitative prediction of class I MHC/epitope binding affinity using QSAR modeling derived from amino acid structural information. , 2015, Combinatorial chemistry & high throughput screening.
[152] J. Thornton,et al. Continuous and discontinuous protein antigenic determinants , 1986, Nature.
[153] C. Watzl,et al. Understanding natural killer cell regulation by mathematical approaches , 2012, Front. Immun..
[154] A. d’Onofrio. A general framework for modeling tumor-immune system competition and immunotherapy: Mathematical analysis and biomedical inferences , 2005, 1309.3337.
[155] N. Shastri,et al. Non-conventional sources of peptides presented by MHC class I , 2011, Cellular and Molecular Life Sciences.
[156] T. Barrette,et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. , 2007, Neoplasia.